NOVEL guaA

Abstract: The invention provides guaA polypeptides and polynucleotides encoding guaA polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing guaA polypeptides to screen for antibacterial compounds.

Description: NOVEL guaA RELATED APPLICATIONS This application claims benefit of US Provisional Patent Application Number 60/066,350 filed November 21, 1997 FIELD OF THE INVENTION This invention relates to newly identified polynucleotides and polypeptides. and their production and uses, as well as their vanants, agonists and antagonists, and their uses In particular, the invention relates to novel polynucleotides and polypeptides of the guaA (GMP synthetase) family, hereinafter referred to as "guaA" BACKGROUND OF THE INVENTION The Streptococci make up a medically important genera of microbes known to cause several types of disease in humans, including, for example, otitis media, conjunctivitis, pneumonia, bacteremia, meningitis, sinusitis, pleural empyema and endocarditis, and most particularly meningitis, such as for example infection of cerebrospinal fluid Since its isolation more than 100 years ago, Streptococcus pneumoniae has been one of the more intensively studied microbes For example, much of our early understanding that DNA is, in fact, the genetic matenal was predicated on the work of Gnffith and of Aver}', Macleod and McCarty using this microbe Despite the vast amount of research with S pneumoniae. many questions concerning the virulence of this microbe remain It is particularly preferred to employ Streptococcal genes and gene products as targets for the development of antibiotics The frequency of Streptococcus pneumoniae infections has πsen dramatιcallγ in the past few decades This has been attributed to the emergence of multiply antibiotic resistant strains and an increasing populanon of people with weakened immune systems It is no longer uncommon to isolate Streptococcus pneumoniae strains which are resistant to some or all of the standard antibiotics This phenomenon has created a demand for both new anti-microbial agents, vaccines, and diagnostic tests for this organism Clearly, there exists a need for factors, such as the guaA embodiments of the invention, that have a present benefit of being useful to screen compounds for antibiotic activity Such factors are also useful to determine their role in pathogenesis of infection, dysfunction and disease There is also a need for identification and characterization of such factors and their antagonists and agonists to find ways to prevent, ameliorate or correct such infection, dysfunction and disease Certain of the polypeptides of the mvention possess ammo acid sequence homology to a known B subtihs guaA protein See Swiss-prot, Accession Number P29727 Also see Borriss R, Porwollik S, Schroeter R The 52 degrees-55 degrees segment of the Bacillus subtihs chromosome a region devoted to purme uptake and metabolism, and containing the genes cotA, gabP and guaA and the pur gene cluster withm a 34960 bp nucleotide sequence Microbiology 1996 Nov, 142 ( Pt 11) 3027-3031, and Mantsala P, Zalkin H Cloning and sequence of Bacillus subtihs purA and guaA. involved in the conversion of IMP to AMP and GMP J Bacteπol 1992 Mar, 174(6) 1883-1890 SUMMARY OF THE INVENTION It is an object of the mvention to provide polypeptides that have been identified as novel guaA polypeptides by homology between the ammo acid sequence set out m Table 1 [SEQ ID NO 2] and a known ammo acid sequence or sequences of other proteins such as B subtihs guaA protem It is a further object of the mvention to provide polynucleotides that encode guaA polypeptides, particularly polynucleotides that encode the polypeptide herem designated guaA In a particularly preferred embodiment of the mvention the polynucleotide compnses a region encodmg guaA polypeptides compnsmg a sequence set out m Table 1 [SEQ LD NO 1] which mcludes a full length gene, or a variant thereof In another particularly preferred embodiment of the invention there is a novel guaA protein from Streptococcus pneumoniae comprising the amino acid sequence of Table 1 [SEQ ID NO 2], or a variant thereof In accordance with another aspect of the mvention there is provided an isolated nucleic acid molecule encodmg a mature polypeptide expressible by the Streptococcus pneumoniae 0100993 stram contamed in the deposited stram A further aspect of the mvention there are provided isolated nucleic acid molecules encodmg guaA particularly Streptococcus pneumoniae guaA, mcludmg mRNAs, cDNAs, genomic DNAs Further embodiments of the mvention mclude biologically, diagnostically, prophylacucally. clinically or therapeutically useful variants thereof, and compositions compπsmg the same In accordance with another aspect of the invention, there is provided the use of a polynucleotide of the mvention for therapeutic or prophylactic purposes, m particular genetic immunization Among the particularly preferred embodiments of the mvention are naturally occurring allelic vanants of guaA and polypeptides encoded thereby Another aspect of the mvention there are provided novel polypeptides of Streptococcus pneumoniae referred to herem as guaA as well as biologically, diagnostically, prophylactically. clinically or therapeutically useful vanants thereof, and compositions compnsmg the same Among the particularly preferred embodiments of the mvention are vanants of guaA polypeptide encoded by naturally occurring alleles of the guaA gene In a preferred embodiment of the mvention there are provided methods for producmg the aforementioned guaA polypeptides In accordance with yet another aspect of the invention, there are provided inhibitors to such polypeptides, useful as antibacterial agents, including, for example, antibodies In accordance with certam preferred embodiments of the mvention, there are provided products, compositions and methods for assessmg guaA expression, treatmg disease, assaying genetic vanation, and admmistenng a guaA polypeptide or polynucleotide to an organism to raise an immunological response against a bactena, especially a Streptococcus pneumoniae bactena In accordance with certam preferred embodiments of this and other aspects of the mvention there are provided polynucleotides that hybndize to guaA polynucleotide sequences, particularly under stnngent conditions In certam preferred embodiments of the mvention there are provided antibodies against guaA polypeptides In other embodiments of the mvention there are provided methods for identifying compounds which bmd to or otherwise mteract with and inhibit or activate an activity of a polypeptide or polynucleotide of the mvention compnsmg contacting a polypeptide or polynucleotide of the mvention with a compound to be screened under conditions to permit bmdmg to or other mteraction between the compound and the polypeptide or polynucleotide to assess the bmdmg to or other mteraction with the compound, such bmdmg or mteraction bemg associated with a second component capable of providmg a detectable signal m response to the bmdmg or mteraction of the polypeptide or polynucleotide w th the compound, and determining whether the compound bmds to or otherwise interacts with and activates or inhibits an activity of the polypeptide or polynucleotide by detectmg the presence or absence of a signal generated from the bmdmg or mteraction of the compound with the polypeptide or polynucleotide In accordance with yet another aspect of the mvention. there are provided guaA agonists and antagonists, preferably bactenostatic or bactenocidal agonists and antagonists In a further aspect of the mvention there are provided compositions compnsmg a guaA polynucleotide or a guaA polypeptide for administration to a cell or to a multicellular organism Vanous changes and modifications withm the spirit and scope of the disclosed mvention will become readily apparent to those skilled m the art from readmg the followmg descriptions and from readmg the other parts of the present disclosure DESCRIPTION OF THE INVENTION The mvention relates to novel guaA polypeptides and polynucleotides as descnbed m greater detail below In particular, the mvention relates to polypeptides and polynucleotides of a novel guaA of Streptococcus pneumoniae, which is related by ammo acid sequence homology to B subtihs guaA polypeptide The mvention relates especially to guaA havmg the nucleotide and ammo acid sequences set out m Table 1 as SEQ ID NO 1 and SEQ ID NO 2 respectively, and to the guaA nucleotide sequences of the DNA m the deposited stram and ammo acid sequences encoded thereby TABLE 1 guaA Polynucleotide and Polypeptide Sequences (A) Sequences from Streptococcus pneumoniae guaA polynucleotide sequence [SEQ ID NO 1] 5'-l CTGATTTGCC AAGATGTAGA AAAAATCATC GGTATTGGGA CTATGGGTAG 51 CCAGTACAAC CAGCTGATTT CACGCCGTAT CCGTGAGATT GGTGTTTTTT 101 CAGAACTAAA AAGCCATAAA ATTTCAGCTG CTGAAGTTCG TGAAGTCAAT 151 CCTGTAGGAA TTATTCTATC AGGTGATCCA AATTCTGTAT ATGAAGATGG 201 TTCATTTGAC ATTGACCCAG AAATCTTCGA ACTAGGAATT CCAATTTTGG 251 GAATCTGTTA TGGTATGCAG TTATTGACCC ATAAACTTGG AGGAAAAGTT 301 GTTCCTGCAG GTGATGCTGG AAATCGTGAA TACGGTCAAT CAACCCTAAC 351 TCACACACCA TCAGCGCAAT TTGAATCAAC ACCTGATGAA CAGACTGTTT 401 TGATGAGCCA TGGTGATGCG GTTACTGAGA TTCCTGCTGA CTTTGTTCGT 451 ACAGGTACAT CAGCTGACTG CCCATACGCA GCCATCGAAA ACCCAGATAA 501 ACACATTTAC GGTATCCAAT TCCACCCAGA AGTTCGTCAT TCTGTATACG 551 GAAATGATAT CCTTCGTAAC TTTGCCCTTA ACATTTGTAA GGCTAAAGGT 601 GACTGGTCAA TGGATAATTT CATTGACATG CAGATCAAAA AAATTCGTGA 651 AACCGTCGGT GATAAACGTG TCCTTCTTGG TCTATCAGGT GGTGTTGACT 701 CATCTGTCGT TGGGGTTCTT CTCCAAAAAG CGATTGGCGA TCAATTGATC 751 TGTATCTTCG TAGACCACGG TCTTCTTCGT AAAGGCGAAG CTGATCAAGT 101 TATGGACATG CTCGGTGGTA AGTTTGGTTT GAATATCGTC AAAGCAGACG 351 CTGCTAAACG TTTCCTTGAC AAACTTGCTG GCGTTTCTGA CCCTGAACAA 901 AAACGTAAAA TCATCGGTAA CGAGTTTGTC TATGTATTCG ATGACGAAGC 951 AAGCAAGCTC AAAGATGTGA AATTCCTTGC TCAAGGTACT TTATATACAG 1001 ATGTTATCGA GTCTGGTACG GATACAGCTC AAACTATCAA GTCACACCAC 1051 AACGTGGGTG GTCTTCCAGA AGATATGCAG TTTGAATTGA TTGAACCACT 1101 CAATACTCTT TACAAGGATG AAGTTCGTGC TCTTGGTACA GAGCTTGGTA 1151 TGCCAGACCA TATCGTATGG CGCCAACCAT TCCCAGGACC AGGACTTGCT 1201 ATCCGTGTCA TGGGTGAAAT CACTGAAGAG AAACTTGAAA CCGTTCGTGA 1251 ATCAGACGCT ATTCTTCGTG AAGAAATCGC TAAAGCTGGA CTTGACCGCG 1301 ATATTTGGCA ATACTTCACT GTTAACACAG GCGTTCGTTC AGTCGGCGTT 1351 ATGGGTGACG GTCGTACGTA TGACTACACG ATTGCAATCC GTGCTATCAC 1401 TTCTATCGAT GGTATGACTG CTGATTTTGC CAAAATTCCA TGGGAAGTAC 1451 TTCAAAAAAT CTCAGTACGT ATCGTAAATG AAGTGGATCA TGTTAACCGT 1501 ATCGTCTACG ATATTACAAG TAAACCACCT GCAACAGTTG AGTGGGAATA 1551 A -3 1 (B) Streptococcus pneumoniae guaA polypeptide sequence deduced from the polynucleotide sequence in this table [SEQ ID NO 2] NH 2 -1 LICQDVEKII GIGTMGSQYN QLISRRIREI GVFSELKSHK ISAAEVREVN 51 PVGIILSGDP NSVYEDGSFD IDPEIFELGI PILGICYGMQ LLTHKLGGKV 101 VPAGDAGNRE YGQSTLTHTP SAQFESTPDE QTVLMSHGDA VTEIPADFVR 151 TGTSADCPYA AIENPDKHIY GIQFHPEVRH SVYGNDILRN FALNICKAKG 201 DWSMDNFIDM QIKKIRETVG DKRVLLGLSG GVDSSWGVL LQKAIGDQLI 251 CIFVDHGLLR KGEADQVMDM LGGKFGLNIV KADAAKRFLD KLAGVSDPEQ 301 KRKIIGNEFV YVFDDEASKL KDVKFLAQGT LYTDVIESGT DTAQTIKSHH 351 NVGGLPEDMQ FELIEPLNTL YKDEVRALGT ELGMPDHI RQPFPGPGLA 401 IRVMGEITEE KLETVRESDA ILREEIAKAG LDRDIWQYFT VNTGVRSVGV 451 MGDGRTYDYT IAIRAITSID GMTADFAKIP WEVLQKISVR IV EVDHVNR 501 IVYDITSKPP ATVEWE -COOH Deposited materials A deposit containmg a Streptococcus pneumoniae 0100993 stram has been deposited with the National Collections of Industnal and Marme Bactena Ltd (herem "NCIMB"), 23 St Machar Dnve. Aberdeen AB2 1RY, Scotland on 11 Apnl 1996 and assigned deposit number 40794 The deposit was descnbed as Streptococcus peumnoiae 0100993 on deposit On 17 Apnl 1996, a Streptococcus peumnoiae 0100993 DNA library m E cob was similarly deposited with the NCIMB and assigned deposit number 40800 The Streptococcus pneumoniae stram deposit is referred to herem as "the deposited stram" or as "the DNA of the deposited stram " The deposited strain contains the full length guaA gene The sequence of the polynucleotides contamed m the deposited strain, as well as the ammo acid sequence of the polypeptide encoded thereby, are controlling m the event of any conflict with any descnption of sequences herem The deposit of the deposited stram has been made under the terms of the Budapest Treaty on the International Recognition of the Deposit of Micro-organisms for Purposes of Patent Procedure The strain will be irrevocably and without restnction or condition released to the pubhc upon the issuance of a patent The deposited stram is provided merely as convenience to those of skill in the art and is not an admission that a deposit is required for enablement, such as that required under 35 U S C §112 A license may be required to make, use or sell the deposited strain, and compounds denved therefrom, and no such license is hereby granted Polypeptides The polypeptides of the mvention mclude a polypeptide of Table 1 [SEQ ID NO 2] (m particular the mature polypeptide) as well as polypeptides and fragments, particularly those which have the biological activity of guaA and also those which have at least 70% identity to a polypeptide of Table 1 [SEQ ID NO 1] or the relevant portion, preferably at least 80% identity to a polypeptide of Table 1 [SEQ ID NO 2and more preferably at least 90% similanty (more preferably at least 90% identity) to a polypeptide of Table 1 [SEQ ID NO 2] and still more preferably at least 95% similanty (still more preferably at least 95% identity) to a polypeptide of Table 1 [SEQ ID NO 2] and also mclude portions of such polypeptides with such portion of the polypeptide generally containmg at least 30 ammo acids and more preferably at least 50 ammo acids The mvention also mcludes polypeptides of the formula X-(R 1 ) m -(R 2 )-(R 3 ) n -Y wherem, at the ammo termmus. X is hydrogen, and at the carboxyl termmus, Y is hydrogen or a metal. R^ and R3 are any ammo acid residue, m is an mteger between 1 and 1000 or zero, n is an mteger between 1 and 1000 or zero, and R 2 is an ammo acid sequence of the mvention, particularly an ammo acid sequence selected from Table 1 In the formula above R 2 is onented so that its ammo termmal residue is at the left, bound to R j and its carboxy terminal residue is at the nght, bound to R3 Any stretch of ammo acid residues denoted by either R group, where m and/or n is greater than 1. may be either a heteropolymer or a homopolymer, preferably a heteropolymer A fragment is a vanant polypeptide havmg an ammo acid sequence that entirely is the same as part but not all of the ammo acid sequence of the aforementioned polypeptides As with guaA polypeptides fragments may be "free-standing," or compnsed within a larger polypeptide of which they form a part or region, most preferably as a smgle contmuous region, a smgle larger polypeptide Preferred fragments mclude, for example, truncation polypeptides havmg a portion of an ammo acid sequence of Table 1 [SEQ ID NO 2], or of vanants thereof, such as a contmuous senes of residues that mcludes the ammo termmus, or a contmuous senes of residues that mcludes the carboxyl termmus Degradation forms of the polypeptides of the mvention m a host cell, particularly a Streptococcus pneumoniae, are also preferred Further preferred are fragments charactenzed by structural or functional attributes such as fragments that compnse alpha-helix and alpha-helix formmg regions, beta-sheet and beta-sheet-formmg regions, turn and turn-formmg regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate bmdmg region, and high antigemc mdex regions Also preferred are biologically active fragments which are those fragments that mediate activities of guaA, mcludmg those with a similar activity or an improved activity, or with a decreased undesirable activity Also mcluded are those fragments that are antigemc or lmmunogemc in an animal, especially m a human Particularly preferred are fragments compnsmg receptors or domains of enzymes that confer a function essential for viability of Streptococcus pneumoniae or the ability to initiate, or maintain cause disease m an mdividual, particularly a human Vanants that are fragments of the polypeptides of the mvention may be employed for producmg the corresponding full-length polypeptide by peptide synthesis, therefore, these vanants may be employed as intermediates for producmg the full-length polypeptides of the mvention In addition to the standard smgle and triple letter representations for ammo acids, the term "X" or "Xaa" may also be used m descπbmg certam polypeptides of the invention "X" and "Xaa" mean that any of the twenty naturally occurmg ammo acids may appear at such a designated position in the polypeptide sequence Polynucleotides Another aspect of the mvention relates to isolated polynucleotides, mcludmg the full length gene, that encode the guaA polypeptide havmg a deduced ammo acid sequence of Table 1 [SEQ ID NO 2] and polynucleotides closely related thereto and vanants thereof Usmg the information provided herem, such as a polynucleotide sequence set out m Table 1 [SEQ ID NO 1], a polynucleotide of the mvention encodmg guaA polypeptide may be obtamed usmg standard cloning and screening methods, such as those for cloning and sequencmg chromosomal DNA fragments from bactena usmg Streptococcus pneumoniae 0100993 cells as starting matenal, followed by obtainmg a full length clone For example, to obtain a polynucleotide sequence of the invention, such as a sequence given m Table 1 [SEQ ID NO 1], typically a library of clones of chromosomal DNA of Streptococcus pneumoniae 0100993 in E cob or some other suitable host is probed with a radiolabeled ohgonucleotide, preferably a 17-mer or longer, derived from a partial sequence Clones carrying DNA identical to that of the probe can then be distinguished usmg stnngent conditions By sequencmg the individual clones thus identified with sequencmg pnmers designed from the ongmal sequence it is then possible to extend the sequence m both directions to determine the full gene sequence Conveniently, such sequencmg is performed using denatured double stranded DNA prepared from a plasmid clone Suitable techmques are described by Maniatis, T , Fπtsch, E F and Sambrook et al , MOLECULAR CLONING, A LABORATORY MANUAL, 2nd Ed , Cold Sprmg Harbor Laboratory Press, Cold Sprmg Harbor, New York (1989) (see in particular Screening By Hybndization 1 90 and Sequencmg Denatured Double-Stranded DNA Templates 13 70) Illustrative of the mvention, the polynucleotide set out m Table 1 [SEQ ID NO 1] was discovered m a DNA library denved from Streptococcus pneumoniae 0100993 The DNA sequence set out m Table 1 [SEQ ID NO 1] contains an open readmg frame encodmg a protem having about the number of ammo acid residues set forth m Table 1 [SEQ ID NO 2] with a deduced molecular weight that can be calculated usmg ammo acid residue molecular weight values well known m the art The polynucleotide of SEQ ID NO 1, between nucleotide number 1 and the stop codon which begins at nucleotide number 1549 of SEQ ID NO 1, encodes the polypeptide of SEQ ID NO 2 GuaA of the mvention is structurally related to other proteins of the guaA (GMP synthetase) family, as shown by the results of sequencmg the DNA encodmg guaA of the deposited stram See Swiss-prot, Accession Number P29727 Also see Borriss R, Porwollik S, Schroeter R The 52 degrees-55 degrees segment of the Bacillus subtihs chromosome a region devoted to punne uptake and metabolism, and contammg the genes cotA, gabP and guaA and the pur gene cluster withm a 34960 bp nucleotide sequence Microbiology 1996 Nov, 142 ( Pt 11) 3027-3031. and Mantsala P, Zalkm H Cloning and sequence of Bacillus subtihs purA and guaA, mvolved m the conversion of IMP to AMP and GMP J Bactenol 1992 Mar, 174(6) 1883-1890 The mvention provides a polynucleotide sequence identical over its entire length to a coding sequence m Table 1 [SEQ ID NO 1] Also provided by the mvention is the coding sequence for the mature polypeptide or a fragment thereof, by itself as well as the coding sequence for the mature polypeptide or a fragment m readmg frame with other coding sequence, such as those encodmg a leader or secretory sequence, a pre-, or pro- or prepro- protem sequence The polynucleotide may also contam non-coding sequences, mcludmg for example, but not limited to non-coding 5' and 3' sequences, such as the transcnbed, non-translated sequences, termination signals, nbosome bmdmg sites, sequences that stabilize mRNA, mtrons. polyadenvlation signals, and additional coding sequence which encode additional ammo acids For example, a marker sequence that facilitates purification of the fused polypeptide can be encoded In certam embodiments of the mvention, the marker sequence is a hexa-histidine peptide, as provided m the pQE vector (Qiagen. Ine ) and desenbed in Gentz et al , Proc Natl Acad Sci , USA 86 821-824 (1989), or an HA tag (Wilson et al , Cell 37 767 (1984) Polynucleotides of the mvention also mclude, but are not limited to, polynucleotides compnsmg a structural gene and its naturalh associated sequences that control gene expression A prefened embodiment of the mvention is a polynucleotide of compnsmg nucleotide 1 to the nucleotide immediately upstream of or mcludmg nucleotide 1549 set forth in SEQ ID NO 1 of Table 1. both of which encode the guaA polypeptide The mvention also mcludes polynucleotides of the formula X-(Rι) m -(R 2 )-(R 3 ) n -Y wherein, at the 5' end of the molecule, X is hydrogen, and at the 3 ' end of the molecule, Y is hydrogen or a metal, R\ and R3 is any nucleic acid residue, m is an mteger between 1 and 3000 or zero , n is an mteger between 1 and 3000 or zero, and R is a nucleic acid sequence of the mvention, particularly a nucleic acid sequence selected from Table 1 In the polynucleotide formula above R is onented so that its 5' end residue is at the left, bound to R and its 3' end residue is at the nght, bound to R3 Any stretch of nucleic acid residues denoted by either R group, where m and/or n is greater than 1, may be either a heteropolymer or a homopolymer, preferably a heteropolymer In a prefened embodiment m and/or n is an mteger between 1 and 1000. It is most prefened that the polynucleotides of the inventions are denved from Streptococcus pneumoniae, however, they may preferably be obtained from organisms of the same taxonomic genus They may also be obtamed, for example, from organisims of the same taxonomic family or order The term "polynucleotide encodmg a polypeptide" as used herem encompasses polynucleotides that mclude a sequence encodmg a polypeptide of the mvention, particularly a bactenal polypeptide and more particularly a polypeptide of the Streptococcus pneumoniae guaA havmg an ammo acid sequence set out m Table 1 [SEQ ID NO 2] The term also encompasses polynucleotides that mclude a smgle contmuous region or discontinuous regions encodmg the polypeptide (for example, mterrupted by mtegrated phage or an insertion sequence or editmg) together with additional regions, that also may contam coding and/or non-coding sequences The mvention further relates to vanants of the polynucleotides descnbed herem that encode for vanants of the polypeptide havmg a deduced ammo acid sequence of Table 1 [SEQ ID NO 2] Vanants that are fragments of the polynucleotides of the mvention may be used to synthesize full- length polynucleotides of the mvention Further particularly prefened embodiments are polynucleotides encodmg guaA \anants, that have the ammo acid sequence of guaA polypeptide of Table 1 [SEQ LD NO 2] in which several, a few. 5 to 10, 1 to 5. 1 to 3, 2, 1 or no ammo acid residues are substituted, deleted or added, m any combination Especially prefened among these are silent substitutions, additions and deletions, that do not alter the properties and activities of guaA Further prefened embodiments of the mvention are polynucleotides that are at least 70% identical over their entire length to a polynucleotide encodmg guaA polypeptide havmg an ammo acid sequence set out in Table 1 [SEQ ID NO 2], and polynucleotides that are complementary to such polynucleotides Alternatively, most highly prefened are polynucleotides that compnse a region that is at least 80% identical over its entire length to a polynucleotide encoding guaA polypeptide of the deposited stram and polynucleotides complementary thereto In this regard, polynucleotides at least 90% identical over their entire length to the same are particularly prefened, and among these particularly prefened polynucleotides, those with at least 95% are especially prefened Furthermore, those with at least 97% are highly prefened among those with at least 95%, and among these those with at least 98% and at least 99% are particularly highly prefened, with at least 99% bemg the more prefened Prefened embodiments are polynucleotides that encode polypeptides that retain substantially the same biological function or activity as the mature polypeptide encoded by a DNA ofTable l [SEQ ID N0 1] The mvention further relates to polynucleotides that hybndize to the herem above-descnbed sequences In this regard, the mvention especially relates to polynucleotides that hybndize under stnngent conditions to the herem above-descnbed polynucleotides As herem used, the terms "stnngent conditions" and "stnngent hybndization conditions" mean hybndization will occur only if there is at least 95% and preferably at least 97% identity between the sequences An example of stnngent hybridization conditions is overnight incubation at 42°C m a solution compnsmg 50%o formamide, 5x SSC (150mM NaCI, 15mM tnsodium citrate), 50 mM sodium phosphate (pH7 6). 5x Denhardt's solution, 10% dextran sulfate, and 20 micrograms/ml denatured, sheared salmon sperm DNA, followed by washmg the hybridization support m 0 lx SSC at about 65 °C Hybridization and wash conditions are well known and exemplified in Sambrook, et al . Molecular Cloning A Laboratory Manual, Second Edition, Cold Spring Harbor, N Y , (1989), particularly Chapter 11 therein The invention also provides a polynucleotide consisting essentially of a polynucleotide sequence obtainable by screening an appropnate library contaimng the complete gene for a polynucleotide sequence set forth in SEQ ID NO 1 under stringent hybridization conditions with a probe having the sequence of said polynucleotide sequence set forth m SEQ ID NO 1 or a fragment thereof, and isolatmg said DNA sequence Fragments useful for obtaining such a polynucleotide include, for example, probes and primers described elsewhere herein As discussed additionally herem regarding polynucleotide assays of the mvention. for instance, polynucleotides of the mvention as discussed above, may be used as a hybndization probe for R cDNA and genomic DNA to isolate full-length cDNAs and genomic clones encodmg guaA and to isolate cDNA and genomic clones of other genes that have a high sequence similanty to the guaA gene Such probes generally will compnse at least 15 bases Preferably, such probes will have at least 30 bases and may have at least 50 bases Particularly prefened probes will have at least 30 bases and will have 50 bases or less For example, the coding region of the guaA gene may be isolated by screening usmg a DNA sequence provided m Table 1 [SEQ ID NO 1] to synthesize an oligonucleotide probe A labeled oligonucleotide havmg a sequence complementary to that of a gene of the mvention is then used to screen a library of cDNA, genomic DNA or mRNA to determine which members of the library the probe hybndizes to The polynucleotides and polypeptides of the mvention may be employed, for example, as research reagents and matenals for discovery of treatments of and diagnostics for disease, particularly human disease, as further discussed herem relatmg to polynucleotide assays Polynucleotides of the invention that are ohgonucleotides denved from the sequences of Table 1 [SEQ ID NOS 1 or 2] may be used in the processes herem as descnbed, but preferably for PCR, to determine whether or not the polynucleotides identified herem m whole or in part are transcribed m bacteria m infected tissue It is recognized that such sequences will also have utility m diagnosis of the stage of infection and type of infection the pathogen has attained The mvention also provides polynucleotides that may encode a polypeptide that is the mature protem plus additional ammo or carboxyl-terminal ammo acids, or ammo acids lntenor to the mature polypeptide (when the mature form has more than one polypeptide chain, for instance) Such sequences may play a role in processmg of a protem from precursor to a mature form, may allow protem transport, may lengthen or shorten protem half-life or may facilitate manipulation of a protem for assay or production, among other things As generally is the case in vivo, the additional ammo acids may be processed away from the mature protem by cellular enzymes A precursor protem, havmg the mature form of the polypeptide fused to one or more prosequences may be an inactive form of the polypeptide When prosequences are removed such inactive precursors generally are activated Some or all of the prosequences may be removed before activation Generally, such precursors are called proproteins In addition to the standard A, G, C, T/U representations for nucleic acid bases, the term "N" may also be used in describing certam polynucleotides of the mvention "N" means that any of the four DNA or RNA bases may appear at such a designated position in the DNA or RNA sequence, except it is preferred that N is not a base that when taken in combmation with adjacent nucleotide positions, when read m the conect readmg frame, would have the effect of generating a premature termination codon m such reading frame In sum, a polynucleotide of the mvention may encode a mature protein, a mature protem plus a leader sequence (which may be refened to as a preprotem), a precursor of a mature protem havmg one or more prosequences that are not the leader sequences of a preprotem, or a preproprotem, which is a precursor to a proprotein, havmg a leader sequence and one or more prosequences, which generally are removed dunng processmg steps that produce active and mature forms of the polypeptide Vectors, host cells, expression The mvention also relates to vectors that compnse a polynucleotide or polynucleotides of the mvention, host cells that are genetically engmeered with vectors of the mvention and the production of polypeptides of the mvention by recombinant techmques Cell-free translation systems can also be employed to produce such proteins usmg RNAs denved from the DNA constructs of the mvention For recombinant production, host cells can be genetically engmeered to incorporate expression systems or portions thereof or polynucleotides of the mvention Introduction of a polynucleotide mto the host cell can be effected by methods descnbed m many standard laboratory manuals, such as Davis et al, BASIC METHODS IN MOLECULAR BIOLOGY, (1986) and Sambrook et al , MOLECULAR CLONING A LABORATORY MANUAL, 2nd Ed , Cold Sprmg Harbor Laboratory Press, Cold Sprmg Harbor, N Y (1989), such as, calcium phosphate transfection, DEAE-dextran mediated transfection, transvection, micromjection, cationic hpid- mediated transfection. electroporation, transduction, scrape loading, ballistic introduction and infection Representative examples of appropnate hosts mclude bactenal cells, such as streptococci, staphylococci, enterococci E cob, streptomyces and Bacillus subtihs cells, fungal cells, such as yeast cells and Asperg llus cells, insect cells such as Drosophila S2 and Spodoptera Sf9 cells, animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, 293 and Bowes melanoma cells, and plant cells A great vanety of expression systems can be used to produce the polypeptides of the mvention Such vectors mclude, among others, chromosomal, episomal and virus-denved vectors, e g , vectors denved from bactenal plasmids, from bactenophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenovrruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors denved from combinations thereof, such as those denved from plasmid and bactenophage genetic elements, such as cosmids and phagemids The expression system constructs may contain control regions that regulate as well as engender expression Generally, any system or vector suitable to mamtam, propagate or express polynucleotides and/or to express a polypeptide m a host may be used for expression m this regard The appropnate DNA sequence may be inserted mto the expression system by any of a vanety of well-known and routine techmques, such as, for example, those set forth m Sambrook et al , MOLECULAR CLONING, A LABORATORY MANUAL, (supra) For secretion of the translated protem mto the lumen of the endoplasmic reticulum. mto the penplasmic space or mto the extracellular environment, appropnate secretion signals may be incorporated mto the expressed polypeptide These signals may be endogenous to the polypeptide or they may be heterologous signals Polypeptides of the mvention can be recovered and purified from recombmant cell cultures by well-known methods mcludmg ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic mteraction chromatography, affimty chromatography, hydroxylapatite chromatography, and lectm chromatography Most preferably, high performance liquid chromatography is employed for purification Well known techniques for refoldmg protem may be employed to regenerate active conformation when the polypeptide is denatured dunng isolation and or purification Diagnostic Assays This mvention is also related to the use of the guaA polynucleotides of the mvention for use as diagnostic reagents Detection of guaA m a eukaryote, particularly a mammal, and especially a human, will provide a diagnostic method for diagnosis of a disease Eukaryotes (herem also "mdιvιdual(s)"), particularly mammals, and especially humans, particularly those infected or suspected to be infected with an organism compnsmg the guaA gene may be detected at the nucleic acid level by a vanety of techmques Nucleic acids for diagnosis may be obtamed from an infected individual's cells and tissues, such as bone, blood, muscle, cartilage, and skm Genomic DNA may be used directly for detection or may be amplified enzymatically by usmg PCR or other amplification technique pnor to analysis RNA cDNA and genomic DNA may also be used m the same ways Usmg amplification, charactenzation of the species and stram of prokaryote present m an mdividual, may be made by an analysis of the genotype of the prokaryote gene Deletions and insertions can be detected by a change m size of the amplified product m companson to the genotype of a reference sequence Pomt mutations can be identified by hybndizmg amplified DNA to labeled guaA polynucleotide sequences Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences m meltmg temperatures DNA sequence differences may also be detected by alterations m the electrophoretic mobility of the DNA fragments m gels, with or without denaturing agents, or by direct DNA sequencmg See, e g , Myers et al , Science, 230 1242 (1985) Sequence changes at specific locations also may be revealed by nuclease protection assays, such as RNase and S 1 protection or a chemical cleavage method See, e g , Cotton et al , Proc Natl Acad Sci , USA, 85 4397-4401 (1985) Cells carrying mutations or polymorphisms m the gene of the mvention may also be detected at the DNA level by a vanety of techmques, to allow for serotypmg, for example For example, RT- PCR can be used to detect mutations It is particularly prefened to used RT-PCR m conjunction with automated detection systems, such as, for example, GeneScan RNA, cDNA or genomic DNA may also be used for the same purpose, PCR or RT-PCR As an example, PCR pnmers complementary to a nucleic acid encoding guaA can be used to identify and analyze mutations Examples of representative pnmers are shown below m Table 2 Table 2 Primers for amplification of guaA polynucleotides SEQ ID NO PRIMER SEQUENCE 3 5'-CAAAAACGTAAAATCATCGGTAAC-3' 4 5'-CAAATATCGCGGTCAAGTCCAG-3' The mvention also mcludes pnmers of the formula X-(R 1 ) m -(R 2 )-(R 3 ) n -Y wherein, at the 5' end of the molecule, X is hydrogen, and at the 3' end of the molecule. Y is hydrogen or a metal, Ri and R3 is any nucleic acid residue, m is an mteger between 1 and 20 or zero , n is an mteger between 1 and 20 or zero, and R 2 is a primer sequence of the mvention, particularly a primer sequence selected from Table 2 In the polynucleotide formula above R is onented so that its 5' end residue is at the left, bound to Rj and its 3' end residue is at the nght, bound to R3 Any stretch of nucleic acid residues denoted by either R group, where m and/or n is greater than 1, may be either a heteropolymer or a homopolymer, preferably a heteropolymer bemg complementary to a region of a polynucleotide of Table 1 In a prefened embodiment m and/or n is an mteger between 1 and 10. The mvention further provides these pnmers with 1, 2. 3 or 4 nucleotides removed from the 5' and/or the 3' end These pnmers may be used for. among other things, amplifying guaA DNA isolated from a sample denved from an mdividual The pnmers may be used to amplify the gene isolated from an infected mdividual such that the gene may then be subject to vanous techmques for elucidation of the DNA sequence In this way, mutations m the DNA sequence may be detected and used to diagnose infection and to serotype and/or classify the infectious agent The mvention further provides a process for diagnosmg, disease, preferably bactenal infections, more preferably infections by Streptococcus pneumoniae, compnsmg determining from a sample derived from an individual a increased level of expression of polynucleotide havmg a sequence of Table 1 [SEQ ID NO 1] Increased or decreased expression of guaA polynucleotide can be measured using any on of the methods well known in the art for the quantation of polynucleotides, such as, for example, amplification, PCR, RT-PCR, RNase protection, Northern blotting and other hybndization methods In addition, a diagnostic assay m accordance with the mvention for detectmg over- expression of guaA protem compared to normal control tissue samples may be used to detect the presence of an infection, for example Assay techmques that can be used to determine levels of a guaA protem, m a sample denved from a host are well-known to those of skill m the art Such assay methods mclude radioimmunoassays, competitive-bmdmg assays, Western Blot analysis and ELISA assays Antibodies The polypeptides of the mvention or vanants thereof, or cells expressmg them can be used as an immunogen to produce antibodies lmmunospecific for such polypeptides "Antibodies" as used herem mcludes monoclonal and polyclonal antibodies, chimenc, smgle cham, simiamzed antibodies and humanized antibodies, as well as Fab fragments, mcludmg the products of an Fab immunolglobulm expression library Antibodies generated against the polypeptides of the mvention can be obtamed by admmistenng the polypeptides or epitope-bearmg fragments, analogues or cells to an animal, preferably a nonhuman, usmg routme protocols For preparation of monoclonal antibodies, any technique known m the art that provides antibodies produced by contmuous cell lme cultures can be used Examples mclude vanous techmques, such as those m Kohler, G and Milstein, C . Nature 256 495-497 (1975), Kozbor et al , Immunology Today 4 72 (1983), Cole et al , pg 77-96 m MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R Liss, Ine (1985) Techmques for the production of smgle cham antibodies (U S Patent No 4,946,778) can be adapted to produce smgle cham antibodies to polypeptides of this mvention Also, transgenic mice, or other organisms such as other mammals, may be used to express humanized antibodies Alternatively phage display technology may be utilized to select antibody genes with bmding activities towards the polypeptide either from repertoires of PCR amplified v-genes of lymphocytes from humans screened for possessing anti-guaA or from naive hbranes (McCafferty, J et al , (1990), Nature 348, 552-554, Marks, J et al , (1992) Biotechnology 10, 779-783) The affimty of these antibodies can also be improved by cham shuffling (Clackson, T et al , (1991) Nature 352, 624-628) If two antigen bmdmg domains are present each domain may be directed against a different epitope - termed 'bispecific' antibodies The above-descnbed antibodies may be employed to isolate or to identify clones expressmg the polypeptides to purify the polypeptides by affimty chromatography Thus, among others, antibodies against guaA- polypeptide may be employed to treat infections, particularly bactenal infections Polypeptide variants mclude antigenically, epitopically or lmmunologically equivalent vanants that form a particular aspect of this invention The term "antigenically equivalent denvative" as used herein encompasses a polypeptide or its equivalent which will be specifically recogmzed by certam antibodies which, when raised to the protein or polypeptide accordmg to the mvention, mterfere with the immediate physical interaction between pathogen and mammalian host The term "lmmunologically equivalent derivative" as used herein encompasses a peptide or its equivalent which when used in a suitable formulation to raise antibodies m a vertebrate, the antibodies act to mterfere with the immediate physical mteraction between pathogen and mammalian host The polypeptide, such as an antigenically or lmmunologically equivalent denvative or a fusion protem thereof is used as an antigen to immunize a mouse or other animal such as a rat or chicken The fusion protem may provide stability to the polypeptide The antigen may be associated, for example by conjugation, with an immunogemc earner protem for example bovine serum albumin (BSA) or keyhole limpet haemocyanin (KLH) Alternatively a multiple antigemc peptide compnsmg multiple copies of the protein or polypeptide, or an antigenically or lmmunologically equivalent polypeptide thereof may be sufficiently antigemc to improve lmmunogenicity so as to obviate the use of a earner Preferably, the antibody or vanant thereof is modified to make it less immunogemc the mdividual For example, if the mdividual is human the antibody may most preferably be "humanized", where the comphmentanty determining regιon(s) of the hybπdoma-denved antibody has been transplanted mto a human monoclonal antibody , for example as described in Jones, P et al (1986), Nature 321, 522-525 or Tempest et al , (1991) Biotechnology 9, 266-273 The use of a polynucleotide of the mvention in genetic immunization will preferably employ a suitable delivery method such as direct injection of plasmid DNA into muscles (Wolff et al . Hum Mol Genet 1992, 1 363, Manthorpe et al , Hum Gene Ther 1963 4, 419), delivery of DNA complexed with specific protem carriers (Wu et al , J Biol Chem 1989 264.16985), coprecipitation of DNA with calcium phosphate (Benvemsty & Reshef, PNAS USA, 1986 83,9551), encapsulation of DNA m various forms of liposomes (Kaneda et al . Science 1989 243,375), particle bombardment (Tang et al , Nature 1992, 356 152, Eisenbraun et al , DNA Cell Biol 1993, 12 791) and in v vo infection using cloned retroviral vectors (Seeger et ai , PNAS USA 1984 81,5849) Antagonists and agonists - assays and molecules Polypeptides of the mvention may also be used to assess the bmdmg of small molecule substrates and ligands m, for example, cells, cell-free preparations, chemical hbranes, and natural product mixtures These substrates and ligands may be natural substrates and ligands or may be structural or functional mimetics See, e g , Cohgan et αl , Current Protocols in Immunology 1(2) Chapter 5 (1991) The mvention also provides a method of screening compounds to identify those which enhance (agomst) or block (antagomst) the action of guaA polypeptides or polynucleotides, particularly those compounds that are bactenostatic and/or bactenocidal The method of screening may mvolve high-throughput techmques For example, to screen for agomsts or antagoists, a synthetic reaction mix, a cellular compartment, such as a membrane, cell envelope or cell wall, or a preparation of any thereof, compnsmg guaA polypeptide and a labeled substrate or ligand of such polypeptide is mcubated m the absence or the presence of a candidate molecule that may be a guaA agomst or antagomst The ability of the candidate molecule to agonize or antagonize the guaA polypeptide is reflected m decreased bmdmg of the labeled ligand or decreased production of product from such substrate Molecules that bmd gratuitously, i e . without mducmg the effects of guaA polypeptide are most likely to be good antagomsts Molecules that bmd well and mcrease the rate of product production from substrate are agomsts Detection of the rate or level of production of product from substrate may be enhanced by usmg a reporter system Reporter systems that may be useful m this regard mclude but are not limited to colonmetnc labeled substrate converted mto product, a reporter gene that is responsive to changes m guaA polynucleotide or polypeptide activity, and bmdmg assays known m the art Another example of an assay for guaA antagomsts is a competitive assay that combines guaA and a potential antagomst with guaA-binding molecules, recombmant guaA bmdmg molecules, natural substrates or hgands, or substrate or ligand mimetics, under appropπate conditions for a competitive inhibition assay guaA can be labeled, such as by radioactivity or a colonmetnc compound, such that the number of guaA molecules bound to a bmdmg molecule or converted to product can be determined accurately to assess the effectiveness of the potential antagomst Potential antagomsts mclude small orgamc molecules, peptides, polypeptides and antibodies that bmd to a polynucleotide or polypeptide of the mvention and thereby inhibit or extinguish its activity Potential antagomsts also may be small orgamc molecules, a peptide, a polypeptide such as a closely related protem or antibody that bmds the same sites on a bmdmg molecule, such as a bmdmg molecule, without mducmg guaA-induced activities, thereby preventmg the action of guaA by excluding guaA from bmdmg Potential antagomsts mclude a small molecule that bmds to and occupies the bmdmg site of the polypeptide thereby preventmg bmdmg to cellular bmdmg molecules, such that normal biological activity is prevented Examples of small molecules mclude but are not limited to small orgamc molecules, peptides or peptide-like molecules Other potential antagomsts mclude antisense molecules (see Okano, J Neurochem 56 560 (1991), OUGODEOXYNUCLEOTIDES AS ANTISENSE INHIBITORS OF GENE EXPRESSION, CRC Press. Boca Raton, FL (1988). for a descnption of these molecules) Prefened potential antagomsts mclude compounds related to and vanants of guaA Each of the DNA sequences provided herem may be used m the discovery and development of antibacterial compounds The encoded protem, upon expression, can be used as a target for the screenmg of antibacterial drugs Additionally, the DNA sequences encodmg the ammo terminal regions of the encoded protem or Shme-Delgarno or other translation facilitating sequences of the respective mRNA can be used to construct antisense sequences to control the expression of the coding sequence of mterest The invention also provides the use of the polypeptide, polynucleotide or inhibitor of the mvention to interfere with the initial physical mteraction between a pathogen and mammalian host responsible for sequelae of infection In particular the molecules of the invention may be used in the prevention of adhesion of bacteria, m particular gram positive bacteria, to mammalian extracellular matrix protems on m-dwelhng devices or to extracellular matrix protems m wounds, to block guaA protem-mediated mammalian cell mvasion by, for example, initiating phosphorylation of mammalian tyrosme kmases (Rosenshme et al , Infect Immun 60 2211 (1992), to block bactenal adhesion between mammalian extracellular matnx proteins and bactenal guaA protems that mediate tissue damage and, to block the normal progression of pathogenesis m infections initiated other than by the implantation of m-dwellmg devices or by other surgical techmques The antagomsts and agomsts of the mvention may be employed, for instance, to inhibit and treat diseases Hehcobacter pylori (herein H pylori) bacteria infect the stomachs of over one-third of the world's population causmg stomach cancer, ulcers, and gastritis (International Agency for Research on Cancer (1994) Schistosomes, Liver Flukes and Hehcobacter Pylori (International Agency for Research on Cancer, Lyon, France, http //www uicc ch/ecp/ecp2904 htm) Moreover, the international Agency for Research on Cancer recently recogmzed a cause-and- effect relationship between H pylori and gastric adenocarcinoma, classifying the bacterium as a Group I (definite) carcmogen Preferred antimicrobial compounds of the mvention (agomsts and antagomsts of guaA) found using screens provided by the mvention, particularly broad- spectrum antibiotics, should be useful in the treatment of / pylori infection Such treatment should decrease the advent of H pylori -induced cancers, such as gastrointestinal carcmoma Such treatment should also cure gastric ulcers and gastntis Vaccines Another aspect of the mvention relates to a method for mducmg an immunological response m an mdividual, particularly a mammal which comprises moculatmg the mdividual with guaA, or a fragment or vaπant thereof, adequate to produce antibody and/ or T cell immune response to protect said mdividual from infection, particularly bacterial infection and most particularly Streptococcus pneumoniae infection Also provided are methods whereby such immunological response slows bacterial replication Yet another aspect of the mvention relates to a method of mducmg immunological response in an mdividual which comprises dehvenng to such mdividual a nucleic acid vector to direct expression of guaA, or a fragment or a vaπant thereof, for expressing guaA. or a fragment or a variant thereof in vivo m order to mduce an immunological response, such as, to produce antibody and/ or T cell immune response, including, for example, cytokine-producing T cells or cytotoxic T cells, to protect said mdividual from disease, whether that disease is already established withm the mdividual or not One way of admmistenng the gene is by acceleratmg it mto the desired cells as a coatmg on particles or otherwise Such nucleic acid vector may compπse DNA, RNA, a modified nucleic acid, or a DNA/RNA hybrid A further aspect of the mvention relates to an immunological composition which, when mtroduced into an mdividual capable or havmg mduced within it an immunological response, induces an immunological response in such individual to a guaA or protein coded therefrom, wherem the composition comprises a recombmant guaA or protem coded therefrom comprising DNA which codes for and expresses an antigen of said guaA or protem coded therefrom The immunological response may be used therapeutically or prophylactically and may take the form of antibody immunity or cellular immumty such as that arising from CTL or CD4+ T cells A guaA polypeptide or a fragment thereof may be fused with co-protem which may not by itself produce antibodies, but is capable of stabilizing the first protem and producmg a fused protein which will have immunogemc and protective properties Thus fused recombmant protein, preferably further compπses an antigemc co-protem, such as hpoprotem D from Hemophilus mfluenzae, Glutathione-S-transferase (GST) or beta-galactosidase. relatively large co-protems which solubihze the protem and facilitate production and purification thereof Moreover, the co-protein may act as an adjuvant m the sense of providmg a generalized stimulation of the immune system The co-protem may be attached to either the ammo or carboxy termmus of the first protein Provided by this mvention are compositions, particularly vaccine compositions, and methods compπsmg the polypeptides or polynucleotides of the mvention and lmmunostimulatory DNA sequences, such as those descnbed in Sato, Y et al Science 273 352 (1996) Also, provided by this mvention are methods usmg the descnbed polynucleotide or particular fragments thereof which have been shown to encode non-vanable regions of bacterial cell surface protems m DNA constructs used in such genetic immunization experiments m animal models of infection with Streptococcus pneumoniae will be particularly useful for identifymg protein epitopes able to provoke a prophylactic or therapeutic immune response It is believed that this approach will allow for the subsequent preparation of monoclonal antibodies of particular value from the requisite organ of the animal successfully resisting or clearing infection for the development of prophylactic agents or therapeutic treatments of bacterial infection, particularly Streptococcus pneumoniae infection, m mammals, particularly humans The polypeptide may be used as an antigen for vaccination of a host to produce specific antibodies which protect against invasion of bactena, for example by blocking adherence of bactena to damaged tissue Examples of tissue damage mclude wounds m skm or connective tissue caused, e g , by mechanical, chemical or thermal damage or by implantation of indwelling devices, or wounds m the mucous membranes, such as the mouth, mammary glands, urethra or vagma The invention also includes a vaccine formulation which compπses an immunogemc recombinant protein of the invention together with a suitable carrier Since the protem may be broken down m the stomach, it is preferably administered parenterally. mcludmg, for example, admmistration that is subcutaneous, intramuscular, mtravenous, or mtradermal Formulations suitable for parenteral administration mclude aqueous and non-aqueous stenle injection solutions which may contam anti-oxidants, buffers, bacteπostats and solutes which render the formulation lnsotomc with the bodily fluid, preferably the blood, of the individual, and aqueous and non-aqueous sterile suspensions which may mclude suspendmg agents or thickemng agents The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampules and vials and may be stored in a freeze-dπed condition requiring only the addition of the sterile liquid carrier immediately prior to use The vaccine formulation may also mclude adjuvant systems for enhancing the lmmunogenicity of the formulation, such as oil-m water systems and other systems known in the art The dosage will depend on the specific activity of the vaccme and can be readily determined by routme experimentation While the mvention has been described with reference to certam guaA protem. it is to be understood that this covers fragments of the naturally occurring protein and similar protems with additions, deletions or substitutions which do not substantially affect the immunogemc properties of the recombmant protein Compositions, kits and administration The mvention also relates to compositions compnsmg the polynucleotide or the polypeptides discussed above or their agomsts or antagomsts The polypeptides of the mvention may be employed m combination with a non-stenle or stenle earner or earners for use with cells, tissues or organisms, such as a pharmaceutical earner suitable for admmistration to a subject Such compositions compnse, for instance, a media additive or a therapeutically effective amount of a polypeptide of the mvention and a pharmaceutically acceptable earner or excipient Such earners may mclude. but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol and combinations thereof The formulation should suit the mode of admmistration The mvention further relates to diagnostic and pharmaceutical packs and kits compπsmg one or more containers filled with one or more of the ingredients of the aforementioned compositions of the mvention Polypeptides and other compounds of the mvention may be employed alone or m conjunction with other compounds, such as therapeutic compounds The pharmaceutical compositions may be admmistered m any effective, convement manner mcludmg, for instance, admmistration by topical, oral, anal, vagmal, mtravenous, mtrapentoneal, intramuscular, subcutaneous, lntranasal or intradermal routes among others In therapy or as a prophylactic, the active agent may be administered to an mdividual as an mjectable composition, for example as a sterile aqueous dispersion, preferably isotomc Alternatively the composition may be formulated for topical application for example in the form of ointments, creams, lotions, eye omtments, eye drops, ear drops, mouthwash, impregnated dressmgs and sutures and aerosols, and may contam appropriate conventional additives, mcludmg, for example, preservatives, solvents to assist drug penetration, and emollients in ointments and creams Such topical formulations may also contam compatible conventional carriers, for example cream or ointment bases, and ethanol or oleyl alcohol for lotions Such carriers may constitute from about 1% to about 98% bv weight of the formulation, more usually they will constitute up to about 80% by weight of the formulation For admmistration to mammals, and particularly humans, it is expected that the daily dosage level of the active agent will be from 0 01 mg/kg to 10 mg/kg, typically around 1 mg/kg The physician in any event will determine the actual dosage which will be most smtable for an mdividual and will vary with the age, weight and response of the particular mdividual The above dosages are exemplary of the average case There can, of course, be mdividual instances where higher or lower dosage ranges are meπted, and such are withm the scope of this mvention In-dwelling devices mclude surgical implants, prosthetic devices and catheters, l e . devices that are mtroduced to the body of an mdividual and remain position for an extended time Such devices mclude, for example, artificial joints, heart valves, pacemakers, vascular grafts, vascular catheters, cerebrospmal fluid shunts, urinary catheters, continuous ambulatory peritoneal dialysis (CAPD) catheters The composition of the mvention may be admmistered by injection to achieve a systemic effect against relevant bacteria shortly before insertion of an m-dwellmg device Treatment may be continued after surgery dunng the m-body time of the device In addition, the composition could also be used to broaden peπoperative cover for any surgical technique to prevent bacterial wound infections, especially Streptococcus pneumoniae wound infections Many orthopaedic surgeons consider that humans with prosthetic joints should be considered for antibiotic prophylaxis before dental treatment that could produce a bacteremia Late deep infection is a serious complication sometimes leading to loss of the prosthetic jomt and is accompanied by significant morbidity and mortality It may therefore be possible to extend the use of the active agent as a replacement for prophylactic antibiotics in this situation In addition to the therapy descnbed above, the compositions of this invention may be used generally as a wound treatment agent to prevent adhesion of bacteria to matrix protems exposed m wound tissue and for prophylactic use in dental treatment as an alternative to, or m conjunction with, antibiotic prophylaxis Alternatively, the composition of the invention may be used to bathe an indwelling device immediately before insertion The active agent will preferably be present at a concentration of 1 μg/ml to lOmg/ml for bathing of wounds or indwelling devices A vaccine composition is conveniently in mjectable form Conventional adjuvants may be employed to enhance the immune response A suitable unit dose for vaccmation is 0 5-5 microgram/kg of antigen, and such dose is preferably admmistered 1-3 times and with an interval of 1 -3 weeks With the indicated dose range, no adverse toxicological effects will be observed with the compounds of the mvention which would preclude their admmistration to suitable individuals Each reference disclosed herein is incorporated by reference herem m its entirety Any patent application to which this application claims pnonty is also incorporated by reference herem in its entirety GLOSSARY The followmg definitions are provided to facilitate understanding of certam terms used frequently herem "Dιsease(s)" means and disease caused by or related to infection by a bactena, mcludmg otitis media, conjunctivitis, pneumonia, bacteremia, meningitis, sinusitis, pleural empyema and endocarditis, and most particularly meningitis, such as for example infection of cerebrospmal fluid "Host cell" is a cell which has been transformed or transfected, or is capable of transformation or transfection by an exogenous polynucleotide sequence "Identity," as known m the art. is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as the case may be, as determined by comparing the sequences In the art, "identity" also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be, as determined by the match between strings of such sequences "Identity" can be readily calculated by known methods, mcludmg but not limited to those descnbed m (Computational Molecular Biology. Lesk, A M , ed . Oxford Umversity Press. New York, 1988, Biocomputing Informatics and Genome Projects, Smith, D W , ed , Academic Press, New York, 1993, Computer Analysis of Sequence Data. Part I, Gnffin, A M , and Gnffin, H G , eds , Humana Press, New Jersey, 1994, Sequence Analysis in Molecular Biology, von Hemje, G , Academic Press, 1987, and Sequence Analysis Primer, Gnbskov. M and Devereux, J , eds , M Stockton Press, New York, 1991, and Caπllo, H . and Lipman, D , SIAM J Applied Math , 48 1073 (1988) Methods to determine identity are designed to give the largest match between the sequences tested Moreover, methods to determine identity are codified m publicly available computer programs Computer program methods to determine identity between two sequences mclude, but are not limited to, the GCG program package (Devereux, J , et al , Nucleic Acids Research 12(1) 387 (1984)), BLASTP, BLASTN, and FASTA (Altschul. S F et al , J Molec Biol 215 403-410 (1990) The BLAST X program is publicly available from NCBI and other sources (BLAST Manual, Altschul, S , et al , NCBI NLM NIH Bethesda, MD 20894, Altschul, S , et al , J Mol Biol 215 403-410 (1990) The well known Smith Waterman algonthm may also be used to determine identity Parameters for polypeptide sequence comparison mclude the followmg Algonthm Needleman and Wunsch, J Mol Biol 48 443-453 (1970) Companson matnx BLOSSUM62 from Henttkoff and Hentikoff. Proc Natl Acad Sci USA 89 10915-10919 (1992) Gap Penalty 12 Gap Length Penalty 4 A program useful with these parameters is publicly available as the "gap" program from Genetics Computer Group, Madison WI The aforementioned parameters are the default parameters for peptide comparisons (along with no penalty for end gaps) Parameters for polynucleotide compaπson mclude the following Algorithm Needleman and Wunsch, J Mol Biol 48 443-453 (1970) Compaπson matπx matches = +10, mismatch = 0 Gap Penalty 50 Gap Length Penalty 3 Available as The "gap" program from Genetics Computer Group, Madison WI These are the default parameters for nucleic acid compansons A preferred meaning for "identity" for polynucleotides and polypeptides, as the case may be, are provided in (1) and (2) below (1) Polynucleotide embodiments further include an isolated polynucleotide comprising a polynucleotide sequence having at least a 50, 60. 70, 80, 85, 90, 95, 97 or 100% identity to the reference sequence of SEQ ID NO 1, wherem said polynucleotide sequence may be identical to the reference sequence of SEQ ID NO 1 or may include up to a certain mteger number of nucleotide alterations as compared to the reference sequence, wherem said alterations are selected from the group consistmg of at least one nucleotide deletion, substitution, mcludmg transition and transversion, or insertion, and wherem said alterations may occur at the 5' or 3' termmal positions of the reference nucleotide sequence or anywhere between those termmal positions, interspersed either individually among the nucleotides in the reference sequence or m one or more contiguous groups within the reference sequence, and wherein said number of nucleotide alterations is determined by multiplying the total number of nucleotides in SEQ ID NO 1 by the mteger defining the percent identity divided by 100 and then subtracting that product from said total number of nucleotides in SEQ ID NO 1, or n n < x n - (x n • y), wherem n n is the number of nucleotide alterations. x n is the total number of nucleotides in SEQ ID NO 1, y is 0 50 for 50%, 0 60 for 60%, 0 70 for 70%, 0 80 for 80%, 0 85 for 85%. 0 90 for 90%, 0 95 for 95%. 0 97 for 97% or 1 00 for 100%, and • is the symbol for the multiplication operator, and wherem any non-mteger product of x n and y is rounded down to the nearest mteger pnor to subtracting it from x n Alterations of a polynucleotide sequence encodmg the polypeptide of SEQ ID NO 2 may create nonsense, missense or frameshift mutations this codmg sequence and thereby alter the polypeptide encoded by the polynucleotide followmg such alterations By way of example, a polynucleotide sequence of the present invention may be identical to the reference sequence of SEQ ID NO 1, that is it may be 100% identical, or it may mclude up to a certain integer number of nucleic acid alterations as compared to the reference sequence such that the percent identity is less than 100% identity Such alterations are selected from the group consisting of at least one nucleic acid deletion, substitution, mcludmg transition and transversion, or insertion, and wherem said alterations may occur at the 5' or 3' termmal positions of the reference polynucleotide sequence or anywhere between those termmal positions, interspersed either individually among the nucleic acids m the reference sequence or in one or more contiguous groups within the reference sequence The number of nucleic acid alterations for a given percent identity is determined by multiplying the total number of nucleic acids m SEQ ID NO 1 by the integer defining the percent identity divided by 100 and then subtractmg that product from said total number of nucleic acids in SEQ ID NO 1, or n n < x n - (x n • y), wherem n n is the number of nucleic acid alterations, x n is the total number of nucleic acids m SEQ ID NO 1, y is, for instance 0 70 for 70%, 0 80 for 80%, 0 85 for 85% etc , • is the symbol for the multiplication operator, and wherem any non-mteger product of x n and y is rounded down to the nearest integer pnor to subtracting it from x n (2) Polypeptide embodiments further include an isolated polypeptide comprising a polypeptide havmg at least a 50,60, 70, 80, 85, 90, 95, 97 or 100% identity to a polypeptide reference sequence of SEQ ID NO 2, wherem said polypeptide sequence may be identical to the reference sequence of SEQ ID NO 2 or may include up to a certain mteger number of ammo acid alterations as compared to the reference sequence, wherem said alterations are selected from the group consistmg of at least one ammo acid deletion, substitution, mcludmg conservative and non- conservative substitution, or insertion, and wherein said alterations may occur at the ammo- or carboxy-termmal positions of the reference polypeptide sequence or anywhere between those termmal positions, interspersed either individually among the ammo acids in the reference sequence or in one or more contiguous groups withm the reference sequence, and wherem said number of ammo acid alterations is determined by multiplying the total number of ammo acids in SEQ ID NO 2 by the integer defining the percent identity divided by 100 and then subtractmg that product from said total number of am o acids in SEQ ID NO 2, or n a ≤ x a " ( x a * y), wherem n a is the number of ammo acid alterations, x a is the total number of ammo acids m SEQ ID NO 2, y is 0 50 for 50%, 0 60 for 60%. 0 70 for 70%, 0 80 for 80%, 0 85 for 85%, 0 90 for 90%. 0 95 for 95%, 0 97 for 97% or 1 00 for 100%, and • is the symbol for the multiplication operator, and wherein any non-mteger product of x a and y is rounded down to the nearest mteger prior to subtractmg it from x a By way of example, a polypeptide sequence of the present invention may be identical to the reference sequence of SEQ ID NO 2, that is it may be 100% identical, or it may mclude up to a certam integer number of amino acid alterations as compared to the reference sequence such that the percent identity is less than 100% identity Such alterations are selected from the group consisting of at least one ammo acid deletion, substitution, including conservative and non- conservative substitution, or insertion, and wherem said alterations may occur at the ammo- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between those terminal positions, mterspersed either individually among the ammo acids in the reference sequence or in one or more contiguous groups withm the reference sequence The number of ammo acid alterations for a given % identity is determined by multiplying the total number of ammo acids m SEQ ID NO 2 by the integer defining the percent identity divided by 100 and then subtractmg that product from said total number of ammo acids m SEQ ID NO 2, or n a < x a (*a • y)> wherem n a is the number of ammo acid alterations, x a is the total number of ammo acids m SEQ ID NO 2, y is, for instance 0 70 for 70%, 0 80 for 80%, 0 85 for 85% etc , and • is the symbol for the multiplication operator, and wherein any non-mteger product of x a and y is rounded down to the nearest mteger prior to subtractmg it from x a "Isolated" means altered "by the hand of man" from its natural state, i e , if it occurs m nature, it has been changed or removed from its onginal environment, or both For example, a polynucleotide or a polypeptide naturally present m a living organism is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting mateπals of its natural state is "isolated", as the term is employed herem "Polynucleotide(s)" generally refers to any polynbonucleotide or polydeoxnbonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA "Polynucleotide(s)" mclude, without limitation, smgle- and double-stranded DNA DNA that is a mixture of smgle- and double- stranded regions or smgle-, double- and tnple-stranded regions, smgle- and double-stranded RNA, and RNA that is mixture of smgle- and double-stranded regions, hybnd molecules compnsmg DNA and RNA that may be single-stranded or, more typically, double-stranded, or tnple-stranded regions, or a mixture of smgle- and double-stranded regions In addition, "polynucleotide" as used herem refers to tnple-stranded regions compnsmg RNA or DNA or both RNA and DNA The strands m such regions may be from the same molecule or from different molecules The regions may mclude all of one or more of the molecules, but more typically mvolve only a region of some of the molecules One of the molecules of a tuple-helical region often is an oligonucleotide As used herein, the term "polynucleotide(s)" also mcludes DNAs or RNAs as descnbed above that contam one or more modified bases Thus, DNAs or RNAs with backbones modified for stability or for other reasons are "polynucleotιde(s)" as that term is mtended herem Moreover, DNAs or RNAs compnsmg unusual bases, such as mosme, or modified bases, such as tntylated bases, to name just two examples, are polynucleotides as the term is used herem It will be appreciated that a great vanety of modifications have been made to DNA and RNA that serve many useful purposes known to those of skill m the art The term "polynucleotide(s)" as it is employed herem embraces such chemically, enzymatically or metabohcally modified forms of polynucleotides, as well as the chemical forms of DNA and RNA characteπstic of viruses and cells, mcludmg, for example, simple and complex cells "Polynucleotide(s)" also embraces short polynucleotides often refened to as ohgonucleotide(s) "Polypeptide(s)" refers to any peptide or protem compnsmg two or more ammo acids jomed to each other by peptide bonds or modified peptide bonds "Polypeptide(s)" refers to both short chains, commonly refened to as peptides, ohgopeptides and ohgomers and to longer chains generally refened to as proteins Polypeptides may contam ammo acids other than the 20 gene encoded ammo acids "Polypeptide(s)" mclude those modified either by natural processes, such as processmg and other post-translational modifications, but also by chemical modification techmques Such modifications are well descnbed m basic texts and m more detailed monographs, as well as m a volummous research hterature, and they are well known to those of skill m the art It will be appreciated that the same type of modification may be present m the same or varying degree at several sites m a given polypeptide Also, a given polypeptide may contam many types of modifications Modifications can occur anywhere m a polypeptide, mcludmg the peptide backbone, the ammo acid side-chains, and the ammo or carboxyl termini Modifications mclude, for example, acetylation, acylation, ADP-nbosylation, amidation, covalent attachment of flavm, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide denvative. covalent attachment of a hpid or hpid denvative, covalent attachment of phosphotidylmositol, cross-hnkmg, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, lodination, methylation, mynstoylation, oxidation, proteolytic processmg, phosphorylation, prenylation, racermzation. glycosylation, hpid attachment, sulfation, gamma- carboxylation of glutamic acid residues, hydroxylation and ADP-nbosylation, selenoylation, sulfation, transfer-RNA mediated addition of ammo acids to proteins, such as arginylation, and ubiquitination See, for instance, PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed , T E Creighton, W H Freeman and Companj', New York (1993) and Wold, F , Posttranslational Protem Modifications Perspectives and Prospects, pgs 1-12 m POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B C Johnson, Ed , Academic Press, New York (1983), Seifter et al , Meth Enzymol 182 626-646 (1990) and Rattan et al , Protein Synthesis Posttranslational Modifications and Aging, Ann N Y Acad Sci 663 48- 62 (1992) Polypeptides may be branched or cychc, with or without branchmg Cychc, branched and branched circular polypeptides may result from post-translational natural processes and may be made by entirely synthetic methods, as well "Vanant(s)" as the term is used herem, is a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide respectively, but retains essential properties A typical variant of a polynucleotide differs in nucleotide sequence from another, reference polynucleotide Changes m the nucleotide sequence of the vaπant may or may not alter the ammo acid sequence of a polypeptide encoded by the reference polynucleotide Nucleotide changes may result m ammo acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below A typical vanant of a polypeptide differs m ammo acid sequence from another, reference polypeptide Generally, differences are limited so that the sequences of the reference polypeptide and the vanant are closely similar overall and, m many regions, identical A vaπant and reference polypeptide may differ in armno acid sequence by one or more substitutions, additions, deletions m any combmation A substituted or mserted ammo acid residue may or may not be one encoded by the genetic code A vaπant of a polynucleotide or polypeptide may be a naturally occurring such as an allehc vaπant, or it may be a variant that is not known to occur naturalh Non- naturally occurrmg variants of polynucleotides and polypeptides may be made by mutagenesis techmques, by direct synthesis, and by other recombmant methods known to skilled artisans EXAMPLES The examples below are earned out usmg standard techmques, which are well known and routme to those of skill m the art, except where otherwise descnbed m detail The examples are illustrative, but do not limit the mvention Example 1 Strain selection, Library Production and Sequencing The polynucleotide havmg a DNA sequence given in Table 1 [SEQ ID NO 1] was obtained from a library of clones of chromosomal DNA of Streptococcus pneumoniae m E cob The sequencmg data from two or more clones contaimng overlappmg Streptococcus pneumoniae DNAs was used to construct the contiguous DNA sequence m SEQ ID NO 1 Libraries may be prepared by routine methods using, for example, Method 1 or 2 below Total cellular DNA is isolated from Streptococcus pneumoniae 0100993 accordmg to standard procedures and size-fractionated by either of two methods Method 1 Total cellular DNA is mechanically sheared by passage through a needle m order to size-fractionate according to standard procedures DNA fragments of up to 1 lkbp m size are rendered blunt by treatment with exonuclease and DNA polymerase, and EcoRI linkers added Fragments are hgated mto the vector Lambda ZapII that has been cut with EcoRI, the library packaged by standard procedures and E cob mfected with the packaged library The library is amplified by standard procedures Method 2 Total cellular DNA is partially hydrolyzed with a one or a combmation of restnction enzymes appropnate to generate a senes of fragments for cloning into library vectors (e g , Rsal, Pall, Alul, Bshl235I), and such fragments are size-fractionated accordmg to standard procedures EcoRI linkers are hgated to the DNA and the fragments then hgated mto the vector Lambda ZapII that have been cut with EcoRI, the library packaged by standard procedures, and E cob infected with the packaged library The library is amplified by standard procedures Example 2 The determination of expression during infection of a gene from Streptococcus pneumoniae Excised lungs from a 48 hour respiratory tract infection of Streptococcus pneumoniae 0100993 in the mouse is efficiently disrupted and processed m the presence of chaotropic agents and RNAase inhibitor to provide a mixture of ammal and bacterial RNA The optimal conditions for disruption and processing to give stable preparations and high yields of bactenal RNA are followed by the use of hybndrsation to a radiolabelled oligonucleotide specific to Streptococcus pneumoniae 16S RNA on Northern blots The RNAase free, DNAase free, DNA and protein free preparations of RNA obtamed are suitable for Reverse Transcnption PCR (RT-PCR) usmg umque primer pairs designed from the sequence of each gene of Streptococcus pneumoniae 0100993 a) Isolation of tissue infected with Streptococcus pneumoniae 0100993 from a mouse animal model of infection (lungs). Streptococcus pneumoniae 0100993 is grown either on TSA 5%horse blood plates or in AGCH medium overnight, 37°C, 5%C0 2 Bactena are then collected and resuspended in phosphate-buffered saline to an A 6 oo of approximately 0 4 Mice are anaesthetized with lsofluorane and 50ml of bactenal suspension (approximately 2 x 10 5 bacteria) is administered intranasally usmg a pipetman Mice are allowed to recover and have food and water ad libitum After 48 hours, the mice are euthanized by carbon dioxide overdose, and lungs are aseptically removed and snap-frozen m liquid mtrogen b) Isolation of Streptococcus pneumoniae 0100993 RNA from infected tissue samples. Infected tissue samples, m 2-ml cryo-strorage tubes, are removed from -80°C storage mto a dry ice ethanol bath In a microbiological safety cabmet the samples are disrupted up to eight at a time while the remaining samples are kept frozen m the dry ice ethanol bath To disrupt the bactena withm the tissue sample, 50-100 mg of the tissue is transfered to a FastRNA tube containing a silica/ceramic matnx (BIO 101) Immediately, 1 ml of extraction reagents (FastRNA reagents, BIO 101) are added to give a sample to reagent volume ratio of approximately 1 to 20 The tubes are shaken m a reciprocatmg shaker (FastPrep FP120, BIO 101) at 6000 rpm for 20-120 sec The crude RNA preparation is extracted with chloroform/isoamyl alcohol, and precipitated with DEPC-treated/Isopropanol Precipitation Solution (BIO 101) RNA preparations are stored m this lsopropanol solution at -80°C if necessary The RNA is pelleted (12.000g for 10 nun ), washed with 75% ethanol (v/v m DEPC-treated water), air-dπed for 5-10 mm, and resuspended in 0 1 ml of DEPC-treated water, followed by 5-10 minutes at 55 °C Finally, after at least 1 minute on ice, 200 umts of Rnasm (Promega) is added RNA preparations are stored at -80 °C for up to one month For longer term storage the RNA precipitate can be stored at the wash stage of the protocol m 75% ethanol for at least one year at -20 °C Quality of the RNA isolated is assessed by running samples on 1% agarose gels 1 x TBE gels stained with ethidium bromide are used to visualise total RNA yields To demonstrate the isolation of bacterial RNA from the mfected tissue 1 x MOPS, 2 2M formaldehyde gels are run and vacuum blotted to Hybond-N (Amersham) The blot is then hybndised with a 32 P- labelled oligonucletide probe, of sequence 5' AACTGAGACTGGCTTTAAGAGATTA 3' [SEQ ID NO 5], specific to 16S rRNA of Streptococcus pneumoniae The size of the hybπdismg band is compared to that of control RNA isolated from in vitro grown Streptococcus pneumoniae 0100993 m the Northern blot Correct sized bacterial 16S rRNA bands can be detected m total RNA samples which show degradation of the mammalian RNA when visualised on TBE gels c) The removal of DNA from Streptococcus pneumoniae-derived RNA. DNA was removed from 50 microgram samples of RNA by a 30 mmute treatment at 37°C with 20 units of RNAase-free DNAasel (GenHunter) in the buffer supplied m a final volume of 57 microhters The DNAase was mactivated and removed by treatment with TRIzol LS Reagent (Gibco BRL, Life Technologies) accordmg to the manufacturers protocol DNAase treated RNA was resuspended in 100 microhtres of DEPC treated water with the addition of Rnasin as described before d) The preparation of cDNA from RNA samples derived from infected tissue. 3 microgram samples of DNAase treated RNA are reverse transcnbed usmg a Superscript Preamphfication System for First Strand cDNA Synthesis kit (Gibco BRL, Life Technologies) accordmg to the manufacturers instructions 150 nanogram of random hexamers is used to prime each reaction Controls without the addition of SuperScπptll reverse transcnptase are also run Both +/-RT samples are treated with RNaseH before proceedmg to the PCR reaction e) The use of PCR to determine the presence of a bacterial cDNA species. PCR reactions are set up on ice in 0 2 ml tubes by addmg the followmg components 43 microhtres PCR Master Mix (Advanced Biotechnologies Ltd ), 1 microhtre PCR pnmers (optimally 18-25 basepairs in length and designed to possess similar annealing temperatures), each pnmer at 10 mM initial concentration, and 5 microhtres cDNA PCR reactions are run on a Perkm Elmer GeneAmp PCR System 9600 as follows 2 mmutes at 94 °C, then 50 cycles of 30 seconds each at 94 °C, 50 °C and 72 °C followed by 7 mmutes at 72 °C and then a hold temperature of 20 °C (the number of cycles is optimally 30-50 to determine the appearance or lack of a PCR product and optimally 8-30 cycles if an estimation of the starting quantity of cDNA from the RT reaction is to be made), 10 microhtre ahquots are then run out on 1% 1 x TBE gels stained with ethidium bromide, with PCR product, if present, sizes estimated by comparison to a 100 bp DNA Ladder (Gibco BRL, Life Technologies) Alternatively if the PCR products are conveniently labelled by the use of a labelled PCR primer (e g labelled at the 5 'end with a dye) a suitable aliquot of the PCR product is run out on a polyacrylamide sequencmg gel and its presence and quantity detected using a suitable gel scanning system (e g ABI Prism™ 377 Sequencer using GeneScan™ software as supplied by Perkm Elmer) RT/PCR controls may mclude +/- reverse transcnptase reactions, 16S rRNA pnmers or DNA specific pπmer pairs designed to produce PCR products from non-transcπbed Streptococcus pneumoniae 0100993 genomic sequences To test the efficiency of the pnmer pairs they are used m DNA PCR with Streptococcus pneumoniae 0100993 total DNA PCR reactions are set up and run as descnbed above usmg approx 1 microgram of DNA in place of the cDNA Pnmer pairs which fail to give the predicted sized product m either DNA PCR or RT/PCR are PCR failures and as such are umnformative Of those which give the conect size product with DNA PCR two classes are distinguished m RT/PCR 1 Genes which are not transcnbed in vivo reproducibly fail to give a product m RT PCR, and 2 Genes which are transcnbed in vivo reproducibly give the correct size product m RT/PCR and show a stronger signal m the +RT samples than the signal (if at all present) m -RT controls

Claims: What is claimed is: 1 An isolated polynucleotide compnsmg a polynucleotide havmg at least a 70% identity to a polynucleotide encodmg a polypeptide compnsmg the ammo acid sequence of SEQ ID NO 2 2 An isolated polynucleotide compnsmg a polynucleotide havmg at least a 70% identity to a polynucleotide encodmg the same mature polypeptide expressed by the guaA gene contamed m the Streptococcus pneumoniae of the deposited stram 3 An isolated polynucleotide compnsmg a polynucleotide encodmg a polypeptide compnsmg an ammo acid sequence which is at least 70% identical to the ammo acid sequence of SEQ ID NO 2 4 An isolated polynucleotide that is complementary to the polynucleotide of claim 1 5 The polynucleotide of Claim 1 wherem the polynucleotide is DNA or RNA 6 The polynucleotide of Claim 1 compnsmg the nucleic acid sequence set forth in SEQ ID NO 1 7 The polynucleotide of Claim 1 compnsmg nucleotide 1 to the stop codon which begins at nucleotide number 1549 set forth m SEQ ID NO 1 8 The polynucleotide of Claim 1 which encodes a polypeptide compnsmg the ammo acid sequence of SEQ ID NO 2 9 A vector compnsmg the polynucleotide of Claim 1 10 A host cell compnsmg the vector of Claim 9 11 A process for producmg a polypeptide compnsmg expressmg from the host cell of Claim 10 a polypeptide encoded by said DNA 12 A process for producmg a guaA polypeptide or fragment compπsmg cultuπng a host of claim 10 under conditions sufficient for the production of said polypeptide or fragment 13 A polypeptide compnsmg an ammo acid sequence which is at least 70% identical to the ammo acid sequence of SEQ ID NO 2 14 A polypeptide compnsmg an ammo acid sequence as set forth m SEQ ID NO 2 15 An antibody against the polypeptide of claim 14 16 An antagomst which inhibits the activity or expression of the polypeptide of claim 14 17 A method for the treatment of an mdividual m need of guaA polypeptide compnsmg admmistenng to the mdividual a therapeutically effective amount of the polypeptide of claim 14 18 A method for the treatment of an mdividual havmg need to inhibit guaA polypeptide compnsmg admmistenng to the mdividual a therapeutically effective amount of the antagomst of Claim 14 19 A process for diagnosing a disease related to expression or activity of the polypeptide of claim 14 m an mdividual compnsmg (a) determinmg a nucleic acid sequence encodmg said polypeptide, and/or (b) analyzing for the presence or amount of said polypeptide m a sample denved from the mdividual 20 A method for identifymg compounds which mteract with and inhibit or activate an activity of the polypeptide of claim 14 compnsmg contacting a composition compnsmg the polypeptide with the compound to be screened under conditions to permit mteraction between the compound and the polypeptide to assess the mteraction of a compound, such mteraction bemg associated with a second component capable of providmg a detectable signal m response to the mteraction of the polypeptide with the compound, and determinmg whether the compound interacts with and activates or inhibits an activity of the polypeptide by detectmg the presence or absence of a signal generated from the mteraction of the compound with the polypeptide 21 A method for mducmg an nnmunological response in a mammal which comprises inoculating the mammal with guaA polypeptide of claim 14, or a fragment or variant thereof, adequate to produce antibody and/or T cell immune response to protect said ammal from disease 22 A method of mducmg unmunological response in a mammal which compnses delivering a nucleic acid vector to direct expression of guaA polypeptide of claim 14, or fragment or a variant thereof, for expressing said guaA polypeptide, or a fragment or a variant thereof in vivo m order to induce an immunological response to produce antibody and/ or T cell immune response to protect said animal from disease

Inventors: BISWAS SANJOY, BROWN JAMES R, SHILLING LISA K, WARREN RICHARD L, ZALACAIN MAGDALENA, BISWAS, SANJOY, BROWN, JAMES, R., SHILLING, LISA, K., WARREN, RICHARD, L., ZALACAIN, MAGDALENA
Applicants: SMITHKLINE BEECHAM CORP, SMITHKLINE BEECHAM CORPORATION
Application year: 1998
Main classification: C12N15
IPC codes: A61K38, A61K39, A61P31, A61P37, C07K14, C07K16, C12N1, C12N5, C12N9, C12N15, C12P21, C12Q1, C12R1, G01N33